Home> Products> Inhibitors> Cevimeline-CAS 107233-08-9
price inquiry for CAS:107233-08-9, Product:Cevimeline
For research use only. We do not sell to patients.

Cevimeline CAS: 107233-08-9

Category: Inhibitors
Product Name: Cevimeline
Cat No: I000333
CAS No: 107233-08-9
Synonyms: SNI-2011; SNI 2011; (±)-cis-2-Methylspiro[1,3-oxathiolane-5,3'-quinuclidine]
Molecular Formula: C10H17NOS
Molecular Weight: 199.32
SMILES: CC1OC2(CN3CCC2CC3)CS1
InChI: 1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m0/s1
InChIKey: WUTYZMFRCNBCHQ-WPRPVWTQSA-N
Solubility: in DMSO > 10 mM
Target: Muscarinic Receptor
Storage: Store at -20°C
CAS 107233-08-9,Cevimeline
  • Description

Cevimeline (cas 107233-08-9), also known as SNI-2011, is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. Cevimeline stimulates the peripheral muscarinic acetylcholine receptors of salivary glands and increases the concentration of Ca+2 in parotic acini and duct cells of rats.  It is used in the treatment of dry mouth associated with sjogren's syndrome. 

  • Spec

Purity: >98%

  • References

1. Nihon Yakurigaku Zasshi. 2002 Oct;120(4):253-8.
[Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its pharmacological profiles and clinical potential in xerostomia].
Shiozawa A(1).
Author information:
(1)Scientific Affairs Department Pharmaceuticals Group, Nippon Kayaku Co. Ltd., Tokyo Fujimi Bldg., 11-2, Fujimi 1-Chome, Chiyoda-ku, Tokyo 102-8172, Japan. akira.shiozawa@nipponkayaku.co.jp
Cevimeline hydrochloride hydrate is a muscarinic receptor agonist with a chemical structure of a quinuclidine. Intraduodenal administration of cevimeline hydrochloride hydrate dose-dependently increased salivary secretion in normal mice and rats, two strains of autoimmune disease mice, and X-irradiated rats. The clinical efficacy of the cevimeline hydrochlide hydrate at 30 mg t.i.d. during 4 weeks has been demonstrated in double blind comparative study with placebo. In addition, its treatments in 52 weeks have increased salivary flow and improved subjective and objective symptoms of patients with xerostomia in Sjögren's syndrome.
2. Adv Exp Med Biol. 2002;506(Pt B):1107-16.
Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome.
Fox RI(1).
Author information:
(1)Allergy and Rheumatology Clinic, Scripps Memorial Hospital and Research Foundation, La Jolla, California, USA.


price inquiry for CAS:107233-08-9, Product:Cevimeline
Advanced Biomart